Cargando…
Translational development of a tumor junction opening technology
Our goal is to overcome treatment resistance in ovarian cancer patients which occurs in most cases after an initial positive response to chemotherapy. A central resistance mechanism is the maintenance of desmoglein-2 (DSG2) positive tight junctions between malignant cells that prevents drug penetrat...
Autores principales: | Kim, Jiho, Li, Chang, Wang, Hongjie, Kaviraj, Swarnendu, Singh, Sanjay, Savergave, Laxman, Raghuwanshi, Arjun, Gil, Sucheol, Germond, Audrey, Baldessari, Audrey, Chen, Bingmae, Roffler, Steve, Fender, Pascal, Drescher, Charles, Carter, Darrick, Lieber, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094124/ https://www.ncbi.nlm.nih.gov/pubmed/35562182 http://dx.doi.org/10.1038/s41598-022-11843-z |
Ejemplares similares
-
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
por: Richter, Maximilian, et al.
Publicado: (2015) -
In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4
por: Wang, Hongjie, et al.
Publicado: (2022) -
In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor
por: Wang, Hongjie, et al.
Publicado: (2022) -
Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors
por: Li, Chang, et al.
Publicado: (2021) -
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy
por: Pitner, Ragan, et al.
Publicado: (2019)